30 results on '"Wehbe F"'
Search Results
2. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ('Three I's') and HIV-Tuberculosis Service Integration in Lower Income Countries
- Author
-
Charles, M.K., Lindegren, M.L., Wester, C.W., Blevins, M., Sterling, T.R., Dung, N.T., Dusingize, J.C., Avit-Edi, D., Durier, N., Castelnuovo, B., Nakigozi, G., Cortes, C.P., Ballif, M., Fenner, L., Ajayi, S., Anastos, K., Bashi, J., Bishai, W., Boulle, A., Braitstein, P., Carriquiry, G., Carter, J.E., Cegielski, P., Chimbetete, C., Davies, M.-A., Diero, L., Duda, S., Egger, M., Eboua, T.F., Gasser, A., Geng, E., Gnokori, J.C., Hardwicke, L., Hoffmann, C., Huebner, R., Kancheya, N., Kiertiburanakul, S., Kim, P., Lameck, D., Leroy, V., Lewden, C., Mandalakas, A., Maskew, M., McKaig, R., Mofenson, L., Mpoudi-Etame, M., Okwara, B., Phiri, S., Prasitsuebsai, W., Petit, A., Prozesky, H., Reid, S.E., Renner, L., Reubenson, G., Sohn, A., Vo, Q., Walker, D., Wehbe, F., Wejse, C., Williams, C., Wood, R., Wools-Kaloustian, K., Yao, Z., Yunihastuti, E., Zhang, F.J., Zhao, H.X., Han, N., Merati, T.P., Wirawan, D.N., Yuliana, F., Ditangco, R., Uy, E., Bantique, R., Phanuphak, P., Ruxrungtham, K., Avihingsanon, A., Khongphattanayothin, M., Sungkanuparph, S., Sanmeema, N., Chaiwarith, R., Sirisanthana, T., Kotarathititum, W., Pham, T.T., Cuong, D.D., Ha, H.L., Nguyen, V.K., Bui, V.H., Nguyen, T.D., Sohn, A.H., Petersen, B., Cooper, D.A., Law, M.G., Jiamsakul, A., Boettiger, D.C., Wati, D.K., Atmikasari, L.P.P., Malino, I.Y., Nallusamy, R., Chan, K.C., Lumbiganon, P., Kosalaraksa, P., Tharnprisan, P., Udomphanit, T., Phongsamart, W., Wittawatmongkol, O., Dung, K.T.K., Lam, N.V., An, P.N., Loan, N.T., Truong, H.K., Du, T.Q., Chau, N.H., Do, C.V., Ha, M.T., Nipathakosol, P., Kariminia, A., Mutimura, E., Gitembagara, A., Tatwangire, J., Izabelle, I., Niyongabo, T., Twizere, C., Baramperanye, E., Edmonds, A., Yotebieng, M., Azinyue, I., Ayangma, L., Dickinson, D., Eley, B., Fritz, C., Garone, D., Giddy, J., MacPhail, P., Moultrie, H., Ndirangu, J., Pestilli, S., Rabie, H., Stringer, J., Technau, K., Graber, C., Kaeser, F., Keiser, O., Cornell, M., Maxwell, N., Zannou, D.M., Ahouada, C., Akakpo, J., Ahomadegbé, C., Gougounon-Houéto, A., Azon-Kouanou, A., Houngbé, F., Sehonou, J., Koumakpaï, S., Alihonou, F., D'Almeida, M., Hodonou, I., Hounhoui, G., Sagbo, G., Tossa-Bagnan, L., Adjide, H., Drabo, J., Bognounou, R., Dienderé, A., Traore, E., Zoungrana, L., Zerbo, B., Sawadogo, A.B., Zoungrana, J., Héma, A., Soré, I., Bado, G., Tapsoba, A., Yé, D., Kouéta, F., Ouedraogo, S., Ouédraogo, R., Hiembo, W., Gansonré, M., Messou, E., Gnokoro, J.C., Koné, M., Kouakou, G.M., Bosse, C.A., Brou, K., Assi, A.I., Chenal, H., Hawerlander, D., Soppi, F., Minga, A., Abo, Y., Yoboue, J.-M., Eholié, S.P., Amego, M.D.N., Andavi, V., Diallo, Z., Ello, F., Tanon, A.K., Koule, S.O., Anzan, K.C., Guehi, C., Aka, E.A., Issouf, K.L., Kouakou, J.-C., N'Gbeche, M.-S., Pety, T., Kouakou, K., Moh, M., Yao, V.A., Folquet, M.A., Dainguy, M.-E., Kouakou, C., Méa-Assande, V.T., Oka-Berete, G., Zobo, N., Acquah, P., Kokora, M.-B., Timité-Konan, M., Ahoussou, L.D., Assouan, J.K., Sami, M.F., Kouadio, C., Goka, B., Welbeck, J., Sackey, A., Owiafe, S.N., Da Silva, Z.J., Paulo, J., Rodrigues, A., Da Silva, D., Medina, C., Oliviera-Souto, I., Østergaard, L., Laursen, A., Sodemann, M., Aaby, P., Fomsgaard, A., Erikstrup, C., Eugen-Olsen, J., Maïga, M.Y., Diakité, F.F., Kalle, A., Katile, D., Traore, H.A., Minta, D., Cissé, T., Dembelé, M., Doumbia, M., Fomba, M., Kaya, A.S., Traoré, A.M., Traoré, H., Toure, A.A., Dicko, F., Sylla, M., Berthé, A., Traoré, H.C., Koïta, A., Koné, N., N'Diaye, C., Coulibaly, S.T., Traoré, M., Traoré, N., Charurat, M., Alim, G., Dapiap, S., Otu, Igbinoba, F., Benson, O., Adebamowo, C., James, J., Obaseki, Osakede, P., Olasode, J., Seydi, M., Sow, P.S., Diop, B., Manga, N.M., Tine, J.M., Bassabi, C.C., Sy, H.S., Ba, A., Diagne, A., Dior, H., Faye, M., Gueye, R.D., Mbaye, A.D., Patassi, A., Kotosso, A., Kariyare, B.G., Gbadamassi, G., Komi, A., Mensah-Zukong, K.E., Pakpame, P., Lawson-Evi, A.K., Atakouma, Y., Takassi, E., Djeha, A., Ephoévigah, A., Djibril, S.E.-H., Dabis, F., Bissagnene, E., Arrivé, E., Coffie, P., Ekouevi, D., Jaquet, A., Sasco, A.J., Amani, D., Azani, J.-C., Balestre, E., Bessekon, S., Bohossou, F., Gilbert, C., Karcher, S., Gonsan, J.M., Le Carrou, J., Lenaud, S., Nchot, C., Malateste, K., Yao, A.R., Siloué, B., Clouet, G., Dosso, M., Doring, A., Kouakou, A., Rabourdin, E., Rivenc, J., Anglaret, X., Ba, B., Essanin, J.B., Ciaranello, A., Datté, S., Desmonde, S., Diby, J.-S.E., Gottlieb, G.S., Horo, A.G., Kangah, S.N., Malvy, D., Meless, D., Mounkaila-Harouna, A., Ndondoki, C., Shiboski, C., Tchounga, B., Thiébaut, R., Wandeler, G., McGowan, C., Cahn, P., Gotuzzo Herencia, José Eduardo, Reyes, M.W., Grinsztejn, B., Pape, J.W., Padgett, D., and Madero, J.S.
- Subjects
0301 basic medicine ,Program evaluation ,Bacterial Diseases ,poverty ,Physiology ,Antitubercular Agents ,lcsh:Medicine ,HIV Infections ,Pathology and Laboratory Medicine ,Occupational safety and health ,Geographical Locations ,0302 clinical medicine ,case finding ,Health care ,lowest income group ,Medicine and Health Sciences ,Coughing ,Medicine ,Infection control ,030212 general & internal medicine ,lcsh:Science ,fever ,Multidisciplinary ,antiretrovirus agent ,adult ,HIV diagnosis and management ,sputum smear ,Vaccination and Immunization ,3. Good health ,Infectious Diseases ,Caribbean Region ,Tuberculosis Diagnosis and Management ,protective equipment ,tuberculosis control ,Research Article ,medicine.medical_specialty ,isoniazid ,Tuberculosis ,Asia ,integrated health care system ,030106 microbiology ,HIV prevention ,Immunology ,Developing country ,Antiretroviral Therapy ,complication ,610 Medicine & health ,World Health Organization ,Article ,03 medical and health sciences ,Signs and Symptoms ,Tuberculosis diagnosis ,Antiviral Therapy ,Human immunodeficiency virus infection ,night sweat ,360 Social problems & social services ,Environmental health ,parasitic diseases ,Isoniazid ,Humans ,purl.org/pe-repo/ocde/ford#3.01.05 [https] ,human ,coughing ,Poverty ,tuberculin test ,Caribbean ,Preventive medicine ,Infection Control ,AIDS-Related Opportunistic Infections ,business.industry ,screening ,lcsh:R ,Biology and Life Sciences ,occupational safety ,South America ,medicine.disease ,Tropical Diseases ,Diagnostic medicine ,mask ,Public and occupational health ,purl.org/pe-repo/ocde/ford#3.02.07 [https] ,People and Places ,Africa ,Physical therapy ,tuberculostatic agent ,lcsh:Q ,weight reduction ,business ,Physiological Processes - Abstract
SETTING World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy (IPT), and infection control ("Three I's") for TB prevention and control among persons living with HIV. OBJECTIVE To assess the implementation of the "Three I's" of TB-control at HIV treatment sites in lower income countries. DESIGN Survey conducted between March-July, 2012 at 47 sites in 26 countries: 6 (13%) Asia Pacific, 7 (15%), Caribbean, Central and South America, 5 (10%) Central Africa, 8 (17%) East Africa, 14 (30%) Southern Africa, and 7 (15%) West Africa. RESULTS ICF using symptom-based screening was performed at 38% of sites; 45% of sites used symptom-screening plus additional diagnostics. IPT at enrollment or ART initiation was implemented in only 17% of sites, with 9% of sites providing IPT to tuberculin-skin-test positive patients. Infection control measures varied: 62% of sites separated smear-positive patients, and healthcare workers used masks at 57% of sites. Only 12 (26%) sites integrated HIV-TB services. Integration was not associated with implementation of TB prevention measures except for IPT provision at enrollment (42% integrated vs. 9% non-integrated; p = 0.03). CONCLUSIONS Implementation of TB screening, IPT provision, and infection control measures was low and variable across regional HIV treatment sites, regardless of integration status.
- Published
- 2016
3. Outcomes After Intensive Care Unit Admission for Patients Receiving Palliative Radiation Therapy: A Missed Opportunity for Goals of Care Discussions
- Author
-
Rakhra, S., primary, Sacotte, R., additional, Wehbe, F., additional, Kruser, J.M., additional, Liu, D., additional, and Kruser, T., additional
- Published
- 2016
- Full Text
- View/download PDF
4. Improving safety performance: Using deviation reporting as a source for continuous improvement
- Author
-
Aslesen, S., Sandberg, E., Farook Hamzeh, and Wehbe, F.
5. Evaluating Methods for the Prediction of Cell Type-Specific Enhancers in the Mammalian Cortex.
- Author
-
Johansen NJ, Kempynck N, Zemke NR, Somasundaram S, De Winter S, Hooper M, Dwivedi D, Lohia R, Wehbe F, Li B, Abaffyová D, Armand EJ, De Man J, Eksi EC, Hecker N, Hulselmans G, Konstantakos V, Mauduit D, Mich JK, Partel G, Daigle TL, Levi BP, Zhang K, Tanaka Y, Gillis J, Ting JT, Ben-Simon Y, Miller J, Ecker JR, Ren B, Aerts S, Lein ES, Tasic B, and Bakken TE
- Abstract
Identifying cell type-specific enhancers in the brain is critical to building genetic tools for investigating the mammalian brain. Computational methods for functional enhancer prediction have been proposed and validated in the fruit fly and not yet the mammalian brain. We organized the 'Brain Initiative Cell Census Network (BICCN) Challenge: Predicting Functional Cell Type-Specific Enhancers from Cross-Species Multi-Omics' to assess machine learning and feature-based methods designed to nominate enhancer DNA sequences to target cell types in the mouse cortex. Methods were evaluated based on in vivo validation data from hundreds of cortical cell type-specific enhancers that were previously packaged into individual AAV vectors and retro-orbitally injected into mice. We find that open chromatin was a key predictor of functional enhancers, and sequence models improved prediction of non-functional enhancers that can be deprioritized as opposed to pursued for in vivo testing. Sequence models also identified cell type-specific transcription factor codes that can guide designs of in silico enhancers. This community challenge establishes a benchmark for enhancer prioritization algorithms and reveals computational approaches and molecular information that are crucial for the identification of functional enhancers for mammalian cortical cell types. The results of this challenge bring us closer to understanding the complex gene regulatory landscape of the mammalian brain and help us design more efficient genetic tools and potential gene therapies for human neurological diseases., Competing Interests: Declaration of interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
6. Northwestern University resource and education development initiatives to advance collaborative artificial intelligence across the learning health system.
- Author
-
Luo Y, Mao C, Sanchez-Pinto LN, Ahmad FS, Naidech A, Rasmussen L, Pacheco JA, Schneider D, Mithal LB, Dresden S, Holmes K, Carson M, Shah SJ, Khan S, Clare S, Wunderink RG, Liu H, Walunas T, Cooper L, Yue F, Wehbe F, Fang D, Liebovitz DM, Markl M, Michelson KN, McColley SA, Green M, Starren J, Ackermann RT, D'Aquila RT, Adams J, Lloyd-Jones D, Chisholm RL, and Kho A
- Abstract
Introduction: The rapid development of artificial intelligence (AI) in healthcare has exposed the unmet need for growing a multidisciplinary workforce that can collaborate effectively in the learning health systems. Maximizing the synergy among multiple teams is critical for Collaborative AI in Healthcare., Methods: We have developed a series of data, tools, and educational resources for cultivating the next generation of multidisciplinary workforce for Collaborative AI in Healthcare. We built bulk-natural language processing pipelines to extract structured information from clinical notes and stored them in common data models. We developed multimodal AI/machine learning (ML) tools and tutorials to enrich the toolbox of the multidisciplinary workforce to analyze multimodal healthcare data. We have created a fertile ground to cross-pollinate clinicians and AI scientists and train the next generation of AI health workforce to collaborate effectively., Results: Our work has democratized access to unstructured health information, AI/ML tools and resources for healthcare, and collaborative education resources. From 2017 to 2022, this has enabled studies in multiple clinical specialties resulting in 68 peer-reviewed publications. In 2022, our cross-discipline efforts converged and institutionalized into the Center for Collaborative AI in Healthcare., Conclusions: Our Collaborative AI in Healthcare initiatives has created valuable educational and practical resources. They have enabled more clinicians, scientists, and hospital administrators to successfully apply AI methods in their daily research and practice, develop closer collaborations, and advanced the institution-level learning health system., Competing Interests: This work was supported by the grants from the National Institutes of Health (NIH) Yuan Luo, Kristi Holmes, Luke Rasmussen, Andrew Naidech, Lazaro Sanchez‐Pinto, Richard Wunderink, Jennifer Pacheco, Matthew Carson, Susan Clare. Kristi Holmes is a member of Learning Health Systems Editorial Board. Donald Lloyd‐Jones serves as a board member of the American Heart Association. Michael Markl receives grant support by Siemens and Circle Cardiovascular Imaging; co‐founder and co‐owner of Third Coast Dynamics. Susanna McColley reports grants from the NIH National Center for Advancing Translational Science, the Centers for Disease Control and Prevention, the Cystic Fibrosis Foundation, and the Rosenau Family Research Foundation. She receives compensation as an advisor to Vertex Pharmaceuticals, Inc. Huiping Liu is the scientific co‐founder of ExoMira Medicine. Justin Starren reports grants from the NIH and Greenwall Foundation. Theresa Walunas receives research funding from Gilead Sciences. Kelly Michelson reports grants from the NIH, Greenwall Foundation, and the Patient‐Centered Outcomes Research Institute. Richard D’Aquila reports grants from the NIH, serving on external advisory boards for NIH‐funded projects, serving on the NIAID AIDS Research Advisory Council, and serving on the editorial board of the Journal of Clinical Investigation. Abel Kho is an advisor to Datavant. Sanjiv Shah is supported by grants from the NIH and AHA. Lee Cooper reports grants from the NIH and has invention disclosures registered at the Northwestern Office of Innovation and New Ventures, consults for Tempus, and advises Veracyte and Targeted Bioscience. Feng Yue is supported by grants from NIH and is a co‐founder of Sariant Therapeutics, Inc. Deyu Fang is co‐founder of ExoMira Medicine. Ronald Ackermann is supported by grants from the NIH, CDC, and the UnitedHealth Group., (© 2024 The Authors. Learning Health Systems published by Wiley Periodicals LLC on behalf of University of Michigan.)
- Published
- 2024
- Full Text
- View/download PDF
7. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
- Author
-
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, and Cristofanilli M
- Subjects
- Humans, Female, Phosphatidylinositol 3-Kinases genetics, Biomarkers, Tumor genetics, Class I Phosphatidylinositol 3-Kinases genetics, Mutation, Circulating Tumor DNA genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism
- Abstract
Background: although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice., Methods: The study analyzed a multi-institutional cohort comprising 703 patients with luminal-like MBC characterized for circulating tumor DNA through next generation sequencing (NGS). Pathway classification was defined based on previous work (i.e., RTK, RAS, RAF, MEK, NRF2, ER, WNT, MYC, P53, cell cycle, notch, PI3K). Single nucleotide variations (SNVs) were annotated for their oncogenicity through OncoKB. Only pathogenic variants were included in the models. Associations among clinical characteristics, pathway classification, and ESR1/PIK3CA codon variants were explored., Results: The results showed a differential pattern of associations for ESR1 and PIK3CA codon variants in terms of co-occurring pathway alterations patterns of metastatic dissemination, and prognosis. ESR1 537 was associated with SNVs in the ER and RAF pathways, CNVs in the MYC pathway and bone metastases, while ESR1 538 with SNVs in the cell cycle pathway and liver metastases. PIK3CA 1047 and 542 were associated with CNVs in the PI3K pathway and with bone metastases., Conclusions: The study demonstrated how ESR1 and PIK3CA codon variants, together with alterations in specific oncogenic pathways, can differentially impact the biology and clinical phenotype of luminal-like MBC. As novel endocrine therapy agents such as selective estrogen receptor degraders (SERDS) and PI3K inhibitors are being developed, these results highlight the pivotal role of ctDNA NGS to describe tumor evolution and optimize clinical decision making., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
8. Generation of ventralized human thalamic organoids with thalamic reticular nucleus.
- Author
-
Kiral FR, Cakir B, Tanaka Y, Kim J, Yang WS, Wehbe F, Kang YJ, Zhong M, Sancer G, Lee SH, Xiang Y, and Park IH
- Subjects
- Humans, Neurons physiology, Organoids, Thalamic Nuclei pathology, Thalamic Nuclei physiology, Thalamus
- Abstract
Human brain organoids provide unique platforms for modeling several aspects of human brain development and pathology. However, current brain organoid systems mostly lack the resolution to recapitulate the development of finer brain structures with subregional identity, including functionally distinct nuclei in the thalamus. Here, we report a method for converting human embryonic stem cells (hESCs) into ventral thalamic organoids (vThOs) with transcriptionally diverse nuclei identities. Notably, single-cell RNA sequencing revealed previously unachieved thalamic patterning with a thalamic reticular nucleus (TRN) signature, a GABAergic nucleus located in the ventral thalamus. Using vThOs, we explored the functions of TRN-specific, disease-associated genes patched domain containing 1 (PTCHD1) and receptor tyrosine-protein kinase (ERBB4) during human thalamic development. Perturbations in PTCHD1 or ERBB4 impaired neuronal functions in vThOs, albeit not affecting the overall thalamic lineage development. Together, vThOs present an experimental model for understanding nuclei-specific development and pathology in the thalamus of the human brain., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
- Author
-
Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, and Cristofanilli M
- Subjects
- Humans, Female, Cyclin-Dependent Kinase 4, Retrospective Studies, Genomics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Circulating Tumor DNA
- Abstract
Purpose: As the continuation beyond progression (BP) of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is becoming increasingly attractive for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), the definition of resistance factors is crucial. The aim of the study was to investigate the impact of CDK 4/6i BP and to explore potential genomic stratification factors., Materials and Methods: We retrospectively analyzed a multi-institutional cohort of patients with HR-positive HER2-negative MBC characterized for circulating tumor DNA through next-generation sequencing before treatment start. Differences across subgroups were analyzed by chi-square test, and survival was tested by univariable and multivariable Cox regression. Further correction was applied by propensity score matching., Results: Among the 214 patients previously exposed to CDK4/6i, 172 were treated with non-CDK4/6i-based treatment (non-CDK) and 42 with CDK4/6i BP. Multivariable analysis showed a significant impact of CDK4/6i BP, TP53 single-nucleotide variants, liver involvement, and treatment line on both progression-free survival (PFS) and overall survival (OS). Propensity score matching confirmed the prognostic role of CDK4/6i BP both for PFS and OS. The favorable impact of CDK4/6i BP was consistent across all subgroups, and a differential benefit was suggested for ESR1 -mutated patients. ESR1 and RB1 mutations were more represented in the CDK4/6i BP subgroup with respect to CDK4/6i upfront., Conclusion: The study highlighted a significant prognostic impact of the CDK4/6i BP strategy with a potential added benefit in patients with ESR1 mutations suggesting the need for an extensive biomarker characterization.
- Published
- 2023
- Full Text
- View/download PDF
10. Acoustic Measures of Dysphonia in Amyotrophic Lateral Sclerosis.
- Author
-
Maffei MF, Green JR, Murton O, Yunusova Y, Rowe HP, Wehbe F, Diana K, Nicholson K, Berry JD, and Connaghan KP
- Subjects
- Humans, Adult, Middle Aged, Aged, Speech Acoustics, Voice Quality, Acoustics, Speech Production Measurement methods, Dysphonia diagnosis, Dysphonia etiology, Amyotrophic Lateral Sclerosis complications
- Abstract
Purpose: Identifying efficacious measures to characterize dysphonia in complex neurodegenerative diseases is key to optimal assessment and intervention. This study evaluates the validity and sensitivity of acoustic features of phonatory disruption in amyotrophic lateral sclerosis (ALS)., Method: Forty-nine individuals with ALS (40-79 years old) were audio-recorded while producing a sustained vowel and continuous speech. Perturbation/noise-based (jitter, shimmer, and harmonics-to-noise ratio) and cepstral/spectral (cepstral peak prominence, low-high spectral ratio, and related features) acoustic measures were extracted. The criterion validity of each measure was assessed using correlations with perceptual voice ratings provided by three speech-language pathologists. Diagnostic accuracy of the acoustic features was evaluated using area-under-the-curve analysis., Results: Perturbation/noise-based and cepstral/spectral features extracted from /a/ were significantly correlated with listener ratings of roughness, breathiness, strain, and overall dysphonia. Fewer and smaller correlations between cepstral/spectral measures and perceptual ratings were observed for the continuous speech task, although post hoc analyses revealed stronger correlations in speakers with less perceptually impaired speech. Area-under-the-curve analyses revealed that multiple acoustic features, particularly from the sustained vowel task, adequately differentiated between individuals with ALS with and without perceptually dysphonic voices., Conclusions: Our findings support using both perturbation/noise-based and cepstral/spectral measures of sustained /a/ to assess phonatory quality in ALS. Results from the continuous speech task suggest that multisubsystem involvement impacts cepstral/spectral analyses in complex motor speech disorders such as ALS. Further investigation of the validity and sensitivity of cepstral/spectral measures during continuous speech in ALS is warranted.
- Published
- 2023
- Full Text
- View/download PDF
11. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
- Author
-
Gerratana L, Movarek M, Wehbe F, Katam N, Mahalingam D, Donahue J, Shah A, Chae YK, Mulcahy M, Tsarwhas D, Villaflor V, Kalyan A, Hussein M, Patel J, Chandra S, Platanias LC, Gradishar W, Cristofanilli M, and Behdad A
- Subjects
- Biomarkers, Tumor genetics, Class I Phosphatidylinositol 3-Kinases, Female, Genomics, Humans, Proto-Oncogene Proteins p21(ras), Retrospective Studies, Breast Neoplasms genetics, Circulating Tumor DNA genetics, Colorectal Neoplasms, Ovarian Neoplasms
- Abstract
Purpose: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for baseline characterization and longitudinal monitoring of a tumor throughout disease management. The aim of this study was to evaluate the utility of ctDNA across a wide spectrum of tumor types., Methods: We retrospectively identified 1,763 patients with advanced cancers who had next-generation sequencing of ctDNA or tumor tissue completed by a designated commercial assay at Northwestern University., Results: ctDNA identified at least one gene alteration in 90% of patients. The number of detected alterations (NDA) and mutant allele frequency (MAF) of the most frequently mutated genes varied significantly across tumor types, with the highest MAF observed in gastric, colorectal, and breast cancers and the highest NDA observed in colorectal, lung squamous, and ovarian/endometrial cancers. TP53 was the most mutated gene in all tumor types. PIK3CA, ERBB2, BRCA1 , and FGFR1 alterations were associated with breast cancer, and ESR1 mutations were exclusively detected in this tumor type. Colorectal cancer was characterized by alterations in KRAS and APC mutations, whereas KRAS, EGFR, PIK3CA , and BRAF mutations were common in lung adenocarcinoma. Concordance between blood and tissue sequencing was notably observed for truncal gene alterations (eg, APC and KRAS ), whereas low concordance was often observed in genes associated with treatment resistance mechanisms (eg, RB1 and NF1 ). Tumor mutational burden (TMB) varied significantly across tumor types, and patients with high MAF or NDA had a significantly higher TMB score with one of the investigated platforms., Conclusion: The study provided new insights into the ctDNA mutational landscape across solid tumors, suggesting new hypotheses-generating data and caveats for future histotype-agnostic workflows integrated with tissue-based biomarkers such as TMB.
- Published
- 2022
- Full Text
- View/download PDF
12. Accelerated Epigenetic Age Among Women with Invasive Cervical Cancer and HIV-Infection in Nigeria.
- Author
-
Musa J, Kim K, Zheng Y, Qu Y, Joyce BT, Wang J, Nannini DR, Gursel DB, Silas O, Abdulkareem FB, Imade G, Akanmu AS, Wei JJ, Kocherginsky M, Kim KA, Wehbe F, Achenbach CJ, Anorlu R, Simon MA, Sagay A, Ogunsola FT, Murphy RL, and Hou L
- Subjects
- Aging genetics, Epigenesis, Genetic, Female, Humans, Nigeria epidemiology, HIV Infections epidemiology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms genetics
- Abstract
Background: Invasive cervical cancer (ICC) is a serious public health burden in Nigeria, where human immunodeficiency virus (HIV) remains highly prevalent. Previous research suggested that epigenetic age acceleration (EAA) could play a role in detection of HIV-associated ICC. However, little research has been conducted on this topic in Africa where the population is most severely affected by HIV-associated ICC. Here, we investigated the association between ICC and EAA using cervical tissues of ICC-diagnosed Nigerian women living with HIV., Methods: We included 116 cervical tissue samples from three groups of Nigerian women in this study: (1) HIV+/ICC+ ( n = 39); (2) HIV+/ICC- ( n = 53); and (3) HIV-/ICC + ( n = 24). We utilized four DNA methylation-based EAA estimators; IEAA, EEAA, GrimAA, and PhenoAA. We compared EAA measurements across the 3 HIV/ICC groups using multiple linear regression models. We also compared EAA between 26 tumor tissues and their surrounding normal tissues using paired t -tests. We additionally performed a receiver operating characteristics (ROC) curve analysis to illustrate the area under the curve (AUC) of EAA in ICC., Results: We found the most striking associations between HIV/ICC status and PhenoAge acceleration (PhenoAA). Among HIV-positive women, PhenoAA was on average 13.4 years higher in women with ICC compared to cancer-free women ( P = 0.005). PhenoAA was 20.7 and 7.1 years higher in tumor tissues compared to surrounding normal tissues among HIV-positive women ( P = 0.009) and HIV-negative women ( P = 0.284), respectively. We did not find substantial differences in PhenoAA between HIV-positive and HIV-negative women with ICC., Conclusion: PhenoAA is associated with ICC in HIV-infected women in our study. Our findings suggest that PhenoAA may serve as a potential biomarker for further risk stratification of HIV-associated ICC in Nigeria and similar resource-constrained settings., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Musa, Kim, Zheng, Qu, Joyce, Wang, Nannini, Gursel, Silas, Abdulkareem, Imade, Akanmu, Wei, Kocherginsky, Kim, Wehbe, Achenbach, Anorlu, Simon, Sagay, Ogunsola, Murphy and Hou.)
- Published
- 2022
- Full Text
- View/download PDF
13. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
- Author
-
Shah AN, Sunderraj A, Finkelman B, See SH, Davis AA, Gerratana L, Wehbe F, Katam N, Mahalingam D, Gradishar WJ, Behdad A, Blanco L, and Cristofanilli M
- Subjects
- Biomarkers, Tumor genetics, DNA Copy Number Variations, High-Throughput Nucleotide Sequencing, Humans, Predictive Value of Tests, Receptor, ErbB-2 genetics, Retrospective Studies, Circulating Tumor DNA genetics, Neoplasms diagnosis, Neoplasms genetics
- Abstract
Background: The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood., Materials and Methods: We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing., Results: 176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast ( n = 67), non-small cell lung ( n = 25), colorectal ( n = 18), gastroesophageal ( n = 17), pancreatic ( n = 11), and uterine ( n = 11). The PPV of ERBB2 CNG in determining HER2 positivity by standard IHC/FISH definitions was 88% for tissue NGS ( n = 57) and 80% for ctDNA ( n = 47). The PPV among breast cancer patients for tissue NGS was 97% ( n = 35) and ctDNA was 93% ( n = 39). However, for non-breast cancer cases, the PPV of ERBB2 amplification by tissue NGS dropped to 76% ( n = 22) and by ctDNA to 44% ( n = 7)., Conclusions: ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer., Competing Interests: CONFLICTS OF INTEREST ANS reports honorarium from AstraZeneca. AB reports speaker fees from Lilly, Roche, Thermo fisher scientific, and Foundation Medicine., (Copyright: © 2022 Shah et al.)
- Published
- 2022
- Full Text
- View/download PDF
14. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
- Author
-
Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, Chen Q, Chen YH, Lu X, Jennings L, Frankfurt O, Altman J, and Sukhanova M
- Subjects
- Adult, Aged, Cytogenetic Analysis, Female, Genomics, Humans, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes pathology, Retrospective Studies, Young Adult, Gene Rearrangement genetics, Leukemia, Myeloid diagnosis, Leukemia, Myeloid genetics, Leukemia, Myeloid pathology, MDS1 and EVI1 Complex Locus Protein genetics, MDS1 and EVI1 Complex Locus Protein metabolism
- Abstract
MECOM rearrangements are recurrent in myeloid neoplasms and associated with poor prognosis. However, only inv(3)(q21q26.2) and t(3;3)(q21;q26.2), the classic MECOM rearrangements resulting in RPN1-MECOM rearrangement with Mecom overexpression and GATA2 haploinsufficiency, define the distinct subtype of acute myeloid leukemia (AML), and serve as presumptive evidence for myelodysplastic syndrome based on the current World Health Organization classification. Myeloid neoplasms with nonclassic 3q26.2/MECOM rearrangements have been found to be clinically aggressive, but comparative analysis of clinicopathologic and genomic features is limited. We retrospectively studied cohorts of myeloid neoplasms with classic and nonclassic MECOM rearrangements. Cases with classic rearrangements consisted predominantly of AML, often with inv(3) or t(3;3) as the sole chromosome abnormality, whereas the group of nonclassic rearrangements included a variety of myeloid neoplasms, often with complex karyotype without TP53 mutations and similarly dismal overall survival. Immunohistochemistry revealed Mecom protein overexpression in both groups, but overexpression in cases with nonclassic rearrangements was mediated through a mechanism other than GATA2 distal enhancer involvement typical for classic rearrangement. Our results demonstrated that myeloid neoplasms with nonclassic 3q26.2/MECOM rearrangements encompass a diverse group of diseases with poor clinical outcome, overexpression of Mecom protein as a result of the nonclassic mechanism of MECOM activation., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
15. Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.
- Author
-
Liu X, Davis AA, Xie F, Gui X, Chen Y, Zhang Q, Gerratana L, Zhang Y, Shah AN, Behdad A, Wehbe F, Huang Y, Yu J, Du P, Jia S, Li H, and Cristofanilli M
- Subjects
- Biomarkers, Tumor, China epidemiology, Female, Genomics, Hormones, Humans, Neoplasm Metastasis, Receptor, ErbB-2 genetics, United States epidemiology, Breast Neoplasms, Cell-Free Nucleic Acids blood, Cell-Free Nucleic Acids genetics, Circulating Tumor DNA blood, Circulating Tumor DNA genetics
- Abstract
Purpose: Meaningful comparison of mutational landscapes across ethnic groups requires the use of standardized platform technology. We have used a harmonized NGS-based liquid biopsy assay to explore the differential genomic landscape of patients with initially hormone receptor-positive (HR+), HER2-negative MBC of first line metastasis or primary Stage IV at diagnosis from the United States (US) and China (CN)., Methods: Plasma circulating tumor DNA (ctDNA) from 27 US patients and 65 CN patients was sequenced using the harmonized CLIA-certified, 152-gene PredicineCare™ liquid biopsy assay. Kaplan-Meier survival analysis was performed to analyze the correlation between genomic alterations and progression-free survival (PFS), and p-values were calculated using the log-rank test., Results: All patients in the CN cohort received chemotherapy and/or hormonal therapy, while 85.2% (23/27) patients in the US cohort received hormonal therapy plus CDK4/6 inhibitors. Mutations were detected in 23 of 27 (85%) US patients and 54 of 65 (83%) CN patients. The prevalence of AKT1 (P = 0.008) and CDH1 (P = 0.021) alterations were both higher in the US vs. CN cohort. In addition, FGFR1 amplification were more frequent in the CN vs. US cohort (P = 0.048). PTEN deletions (P = 0.03) and ESR1 alterations (P = 0.02) were associated with shorter PFS in the CN cohort, neither of these associations were observed in the US cohort. Interestingly, a reduced association between PTEN deletion and PFS was observed in patients receiving CDK4/6 inhibitor treatment., Conclusion: The differential prevalence of ctDNA-based alterations such as FGFR1, AKT1, and CDH1 was observed in initially HR+/HER2- MBC patients in the US vs. CN. In addition, the association of PTEN deletions with shorter PFS was found in the CN but not the US cohort. The differential genomic landscapes across the two ethnic groups may reflect biologic differences and clinical implications., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
16. Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.
- Author
-
Barnea Slonim L, Gao J, Burkart M, Odetola OE, Kocherginsky M, Dinner SN, Lu X, Wehbe F, Jennings L, Altman JK, Mirza KM, Chen YH, and Sukhanova M
- Subjects
- Adult, Genetic Profile, Humans, B-Lymphocytes physiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Tumor Suppressor Protein p53 genetics
- Published
- 2021
- Full Text
- View/download PDF
17. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
- Author
-
Jacob S, Davis AA, Gerratana L, Velimirovic M, Shah AN, Wehbe F, Katam N, Zhang Q, Flaum L, Siziopikou KP, Platanias LC, Gradishar WJ, Behdad A, Bardia A, and Cristofanilli M
- Subjects
- Aged, Breast Neoplasms blood, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Circulating Tumor DNA analysis, Female, Follow-Up Studies, Humans, Middle Aged, Prognosis, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Breast Neoplasms pathology, Circulating Tumor DNA genetics, Drug Resistance, Neoplasm genetics, High-Throughput Nucleotide Sequencing methods, Mutation
- Abstract
Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize genomic evolution in progressive metastatic breast cancer., Experimental Design: This was a retrospective cohort between 2015 and 2019 obtained under an Institutional Review Board-approved protocol at Northwestern University (Chicago, IL). ctDNA samples were analyzed with Guardant360 next-generation sequencing (NGS) assay. A total of 86 patients had at least two serial ctDNA collections with the second drawn at first post-NGS progression (PN1) by imaging and clinical assessment. A total of 27 participants had ctDNA drawn at second post-NGS clinical progression (PN2). We analyzed alterations, mutant allele frequency (MAF), number of alterations (NOA), and sites of disease on imaging in close proximity to ctDNA evaluation. Matched pairs' variations in MAF, NOA, and alterations at progression were tested through Wilcoxon test. We identified an independent control cohort at Massachusetts General Hospital (Boston, MA) of 63 patients with serial ctDNA sampling and no evidence of progression., Results: We identified 44 hormone receptor-positive, 20 HER2
+ , and 22 triple-negative breast cancer cases. The significant alterations observed between baseline and PN1 were TP53 ( P < 0.0075), PIK3CA ( P < 0.0126), AR ( P < 0.0126), FGFR1 ( P < 0.0455), and ESR1 ( P < 0.0143). Paired analyses revealed increased MAF and NOA from baseline to PN1 ( P = 0.0026, and P < 0.0001, respectively). When compared with controls without progression, patients with ctDNA collection at times of progression were associated with increased MAF and NOA ( P = 0.0042 and P < 0.0001, respectively)., Conclusions: Serial ctDNA testing identified resistance alterations and increased NOA and MAF were associated with disease progression. Prospective longitudinal ctDNA evaluation could potentially monitor tumor genomic evolution., (©2020 American Association for Cancer Research.)- Published
- 2021
- Full Text
- View/download PDF
18. Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis.
- Author
-
Waito AA, Wehbe F, Marzouqah R, Barnett C, Shellikeri S, Cui C, Abrahao A, Zinman L, Green JR, and Yunusova Y
- Subjects
- Humans, Judgment, Longitudinal Studies, Reproducibility of Results, Speech Intelligibility, Tongue, Amyotrophic Lateral Sclerosis complications, Amyotrophic Lateral Sclerosis diagnosis, Speech
- Abstract
Purpose Perceptual judgments of articulatory function are commonly used by speech-language pathologists to evaluate articulatory performance in individuals with amyotrophic lateral sclerosis (ALS). The goal of this study was to evaluate the psychometric properties (e.g., reliability, validity) of these perceptual measures to inform their application as part of a comprehensive bulbar assessment tool in ALS. Method Preexisting data from 51 individuals with ALS were obtained from a larger longitudinal study. Five independent raters provided perceptual judgments of articulatory rate and imprecision in a sentence task. Inter- and intrarater reliability of these judgments were assessed. Perceptual ratings were correlated with an acoustic measure of articulatory rate, in syllables per second, obtained from passage-reading recordings. Both perceptual and acoustic measures were correlated with gold-standard kinematic tongue and jaw movement measures, recorded from sentences using electromagnetic articulography. Results The results revealed good inter- and intrarater reliability of perceptual judgments of articulatory function. Strong correlations were observed between perceptual ratings of articulatory rate and imprecision and acoustic measures of articulatory rate and kinematic measures of tongue speed. Conclusions These findings support the clinical application of perceptual judgments of articulatory function as valid and reliable measures of underlying articulatory changes in bulbar ALS. Additional research is needed to understand the responsiveness of these measures to clinical changes in articulatory function in ALS.
- Published
- 2021
- Full Text
- View/download PDF
19. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
- Author
-
Gerratana L, Davis AA, Polano M, Zhang Q, Shah AN, Lin C, Basile D, Toffoli G, Wehbe F, Puglisi F, Behdad A, Platanias LC, Gradishar WJ, and Cristofanilli M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Machine Learning, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Breast Neoplasms diagnosis, Circulating Tumor DNA metabolism, Liquid Biopsy methods, Neoplastic Cells, Circulating metabolism, Precision Medicine methods, Tropism immunology
- Abstract
Background: Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs) enumeration in estimating target organs more susceptible to MBC involvement., Methods: This retrospective study analysed 88 MBC patients characterised for both CTCs and ctDNA at baseline. CTCs were isolated through the CellSearch kit, while ctDNA was analysed using the Guardant360 NGS-based assay. Sites of disease were collected on the basis of imaging. Associations were explored both through uni- and multivariate logistic regression and Fisher's exact test and the random forest machine learning algorithm., Results: After multivariate logistic regression, ESR1 mutation was the only significant factor associated with liver metastases (OR 8.10), while PIK3CA was associated with lung localisations (OR 3.74). CTC enumeration was independently associated with bone metastases (OR 10.41) and TP53 was associated with lymph node localisations (OR 2.98). The metastatic behaviour was further investigated through a random forest machine learning algorithm. Bone involvement was described by CTC enumeration and alterations in ESR1, GATA3, KIT, CDK4 and ERBB2, while subtype, CTC enumeration, inflammatory BC diagnosis, ESR1 and KIT aberrations described liver metastases. PIK3CA, MET, AR, CTC enumeration and TP53 were associated with lung organotropism. The model, moreover, showed that AR, CCNE1, ESR1, MYC and CTC enumeration were the main drivers in HR positive MBC metastatic pattern., Conclusions: These results indicate that ctDNA and CTCs enumeration could provide useful insights regarding MBC organotropism, suggesting a possible role for future monitoring strategies that dynamically focus on high-risk organs defined by tumourbiology., Competing Interests: Conflict of interest statement AAD reports non-financial support from Menarini Silicon Biosystems, outside the submitted work; LG reports non-financial support from Menarini Silicon Biosystems, personal fees from Lilly, outside the submitted work; MC reports grants from National Institutes of Health, during the conduct of the study; personal fees from Pfizer, personal fees from Merus, personal fees from Novartis, personal fees from CytoDyn, outside the submitted work; FP reports grants from AstraZeneca, grants from Eisai, outside the submitted work; all other authors declare no conflict of interest., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Impact of the COVID-19 pandemic on global health research training and education.
- Author
-
Hou L, Mehta SD, Christian E, Joyce B, Lesi O, Anorlu R, Akanmu AS, Imade G, Okeke E, Musah J, Wehbe F, Wei JJ, Gursel D, Klein K, Achenbach CJ, Doobay-Persaud A, Holl J, Maiga M, Traore C, Sagay A, Ogunsola F, and Murphy R
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Young Adult, Biomedical Research education, Biomedical Research organization & administration, COVID-19, Education, Distance organization & administration, Global Health education, Pandemics
- Abstract
Competing Interests: Competing interests: The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no conflicts of interest.
- Published
- 2020
- Full Text
- View/download PDF
21. Landscape of circulating tumour DNA in metastatic breast cancer.
- Author
-
Davis AA, Jacob S, Gerratana L, Shah AN, Wehbe F, Katam N, Zhang Q, Flaum L, Siziopikou KP, Platanias LC, Gradishar WJ, Behdad A, and Cristofanilli M
- Subjects
- Adult, Aged, Breast Neoplasms blood, DNA Copy Number Variations, Female, Gene Frequency, Genetic Heterogeneity, High-Throughput Nucleotide Sequencing, Humans, Middle Aged, Neoplasm Metastasis, Polymorphism, Single Nucleotide, Breast Neoplasms genetics, Circulating Tumor DNA genetics, Gene Regulatory Networks, Sequence Analysis, DNA methods
- Abstract
Background: We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological subtypes of metastatic breast cancer., Methods: 255 clinically annotated patients with ctDNA testing by Guardant360 were stratified into HR+, HER2+, and TNBC cohorts. Frequency and heterogeneity of alterations were reported. Paired ctDNA and tissue sequencing were compared for a subset of patients. The association of ctDNA and metastatic sites of disease on imaging was also assessed., Findings: 89% of patients had at least one ctDNA alteration detected. The most common single nucleotide variants (SNVs) for HR+ patients were PIK3CA, ESR1, and TP53. For HER2+, these were TP53, PIK3CA, and ERBB2 with ERBB2 as the most frequent copy number variant (CNV). For TNBC, the most common SNVs were TP53 and PIK3CA, and the most frequent CNVs were MYC, CCNE1, and PIK3CA. TNBC patients had a significantly higher mutant allele frequency (MAF) of the highest variant compared to HR+ or HER2+ patients (P<0.05). Overall, alterations in PIK3CA, ESR1, and ERBB2 were observed in 39.6%, 16.5%, and 21.6% of patients, respectively. Agreement between blood and tissue was 79-91%. MAF and number of alterations were significantly associated with number of metastatic sites on imaging (P<0.0001)., Interpretation: These data demonstrate the genetic heterogeneity of metastatic breast cancer in blood, the high prevalence of clinically actionable alterations, and the potential to utilise ctDNA as a surrogate for tumour burden on imaging., Funding: Lynn Sage Cancer Research Foundation, OncoSET Precision Medicine Program, and REDCap support was funded by the National Institutes of Health UL1TR001422., Competing Interests: Declaration of Competing Interest Andrew A. Davis reports receiving travel support from Menarini Silicon Biosystems, outside the submitted work; Lorenzo Gerratana reports non-financial support from Menarini Silicon Biosystems, personal fees from Lilly, outside the submitted work; Ami N. Shah reports personal fees from Abbvie, personal fees from Taiho, personal fees from Daiichi-Sankyo, outside the submitted work; Amir Behdad reports personal fees from Pfizer, personal fees from Foundation Medicine, personal fees from Bayer, outside the submitted work. Massimo Cristofanilli reports personal fees from Foundation Medicine, personal fees from Lilly, grants and personal fees from Pfizer, personal fees from Cytodyn, personal fees from Sermonix, grants and personal fees from G1Therapeutics, outside the submitted work., (Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
22. Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
- Author
-
Gerratana L, Zhang Q, Shah AN, Davis AA, Zhang Y, Wehbe F, Qiang W, Flaum L, Finkelman BS, Gradishar WJ, Platanias LC, Behdad A, and Cristofanilli M
- Subjects
- Genomics, Humans, Mutation, Biomarkers, Tumor, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Circulating Tumor DNA, High-Throughput Nucleotide Sequencing
- Abstract
Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
23. HIV status, age at cervical Cancer screening and cervical cytology outcomes in an opportunistic screening setting in Nigeria: a 10-year Cross sectional data analysis.
- Author
-
Musa J, Achenbach CJ, Evans CT, Jordan N, Daru PH, Silas O, Sagay AS, Anorlu R, Mehta SD, Wehbe F, Simon MA, Adewole IF, Hou L, and Murphy RL
- Abstract
Background: Invasive cervical cancer (ICC) is more prevalent in HIV infected women and occurs at younger median age than in HIV negative women. Organized cervical cancer screening (CCS) is presently lacking in Nigeria, and the age at CCS is not known in this population. We sought to examine the age at CCS, the cytology outcomes and whether outcomes differ by HIV infection status in an opportunistic screening setting., Methods: Cross-sectional analysis of data on a sample of women who had received a CCS in an opportunistic screening service in Jos, Nigeria over a 10-year time period (2006-2016). We used logistic regression models to estimate the independent effect of patient-reported HIV and age at CCS and odds ratios for abnormal cytology outcomes adjusting for other covariates. We also assessed the correlation between median age at CCS and severity of abnormal cervical cytology outcomes. Statistical analyses were done on STATA version 14, College Station, Texas, USA., Results: In a sample of 14,088, the median age at CCS was 37 years (IQR; 30-45). For HIV infected women vs. uninfected women, CCS occurred at earlier ages (35.0 ± 7.4 vs 38.2 ± 10.2 years, p < 0.001). All women, regardless of HIV status, who completed at least 7 or more years of education were 1.27 to 3.51 times more likely to have CCS before age 35 than women with less education. The predictors of an abnormal cervical cytology outcome at CCS were: age at CCS ≥ 35 (aOR = 3.57; 95% CI: 2.74, 4.64), multiparity ≥5 (aOR = 1.27; 95% CI: 1.03, 1.56), and provider-referral (aOR = 1.34; 95% CI: 1.09, 1.64). Irrespective of reported HIV status, we found a positive correlation between median age at CCS and severity of cytology outcome., Discussion: The age at CCS in women who have utilized cervical cancer screening in the study population is relatively late compared to the recommended age by most guidelines from developed settings. Late age at CCS correlates positively with severity of abnormal cytology outcome irrespective of HIV status. More educated women are more likely to have CCS at early age and less likely to have underlying abnormal cytology outcomes., Competing Interests: Competing interestsThe authors declare that they have no competing interests., (© The Author(s). 2019.)
- Published
- 2019
- Full Text
- View/download PDF
24. miRNA-Processing Gene Methylation and Cancer Risk.
- Author
-
Joyce BT, Zheng Y, Zhang Z, Liu L, Kocherginsky M, Murphy R, Achenbach CJ, Musa J, Wehbe F, Just A, Shen J, Vokonas P, Schwartz J, Baccarelli AA, and Hou L
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, CpG Islands genetics, DNA Methylation genetics, Epigenesis, Genetic, Female, Humans, Male, MicroRNAs genetics, Neoplasms blood, Neoplasms epidemiology, Oligonucleotide Array Sequence Analysis, Prevalence, Prospective Studies, Surveys and Questionnaires statistics & numerical data, Time Factors, United States epidemiology, United States Department of Veterans Affairs statistics & numerical data, Carcinogenesis genetics, MicroRNAs metabolism, Neoplasms genetics, RNA-Binding Proteins genetics, Ribonuclease III genetics
- Abstract
Background: Dysregulation of miRNA and methylation levels are epigenetic hallmarks of cancer, potentially linked via miRNA-processing genes. Studies have found genetic alterations to miRNA-processing genes in cancer cells and human population studies. Our objective was to prospectively examine changes in DNA methylation of miRNA-processing genes and their associations with cancer risk. Methods: We examined cohort data from the Department of Veterans' Affairs Normative Aging Study. Participants were assessed every 3 to 5 years starting in 1999 through 2013 including questionnaires, medical record review, and blood collection. Blood from 686 consenting participants was analyzed using the Illumina 450K BeadChip array to measure methylation at CpG sites throughout the genome. We selected 19 genes based on a literature review, with 519 corresponding CpG sites. We then used Cox proportional hazards models to examine associations with cancer incidence, and generalized estimating equations to examine associations with cancer prevalence. Associations at false discovery rate < 0.05 were considered statistically significant. Results: Methylation of three CpGs ( DROSHA : cg23230564, TNRC6B : cg06751583, and TNRC6B : cg21034183) was prospectively associated with time to cancer development (positively for cg06751583, inversely for cg23230564 and cg21034183), whereas methylation of one CpG site ( DROSHA : cg16131300) was positively associated with cancer prevalence. Conclusions: DNA methylation of DROSHA , a key miRNA-processing gene, and TNRC6B may play a role in early carcinogenesis. Impact: Changes in miRNA processing may exert multiple effects on cancer development, including protecting against it via altered global miRNAs, and may be a useful early detection biomarker of cancer. Cancer Epidemiol Biomarkers Prev; 27(5); 550-7. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
25. A Machine Learning Algorithm for Identifying Atopic Dermatitis in Adults from Electronic Health Records.
- Author
-
Gustafson E, Pacheco J, Wehbe F, Silverberg J, and Thompson W
- Abstract
The current work aims to identify patients with atopic dermatitis for inclusion in genome-wide association studies (GWAS). Here we describe a machine learning-based phenotype algorithm. Using the electronic health record (EHR), we combined coded information with information extracted from encounter notes as features in a lasso logistic regression. Our algorithm achieves high positive predictive value (PPV) and sensitivity, improving on previous algorithms with low sensitivity. These results demonstrate the utility of natural language processing (NLP) and machine learning for EHR-based phenotyping.
- Published
- 2017
- Full Text
- View/download PDF
26. The CTSA Consortium's Catalog of Assets for Translational and Clinical Health Research (CATCHR).
- Author
-
Shirey-Rice J, Mapes B, Basford M, Zufelt A, Wehbe F, Harris P, Alcorn M, Allen D, Arnim M, Autry S, Briggs MS, Carnegie A, Chavis-Keeling D, De La Pena C, Dworschak D, Earnest J, Grieb T, Guess M, Hafer N, Johnson T, Kasper A, Kopp J, Lockie T, Lombardo V, McHale L, Minogue A, Nunnally B, O'Quinn D, Peck K, Pemberton K, Perry C, Petrie G, Pontello A, Posner R, Rehman B, Roth D, Sacksteder P, Scahill S, Schieri L, Simpson R, Skinner A, Toussant K, Turner A, Van der Put E, Wasser J, Webb CD, Williams M, Wiseman L, Yasko L, and Pulley J
- Subjects
- Data Collection, High-Throughput Screening Assays, Humans, Internet, Reproducibility of Results, User-Computer Interface, Catalogs as Topic, Cooperative Behavior, Health Services Research, Translational Research, Biomedical
- Abstract
The 61 CTSA Consortium sites are home to valuable programs and infrastructure supporting translational science and all are charged with ensuring that such investments translate quickly to improved clinical care. Catalog of Assets for Translational and Clinical Health Research (CATCHR) is the Consortium's effort to collect and make available information on programs and resources to maximize efficiency and facilitate collaborations. By capturing information on a broad range of assets supporting the entire clinical and translational research spectrum, CATCHR aims to provide the necessary infrastructure and processes to establish and maintain an open-access, searchable database of consortium resources to support multisite clinical and translational research studies. Data are collected using rigorous, defined methods, with the resulting information made visible through an integrated, searchable Web-based tool. Additional easy-to-use Web tools assist resource owners in validating and updating resource information over time. In this paper, we discuss the design and scope of the project, data collection methods, current results, and future plans for development and sustainability. With increasing pressure on research programs to avoid redundancy, CATCHR aims to make available information on programs and core facilities to maximize efficient use of resources., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
27. Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America.
- Author
-
Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, Boulle A, Wehbe F, Masys D, Iriondo-Perez J, Hemingway-Foday J, and Law M
- Subjects
- Adolescent, Adult, Africa South of the Sahara epidemiology, Anemia blood, Anemia epidemiology, Anti-HIV Agents therapeutic use, Cohort Studies, Female, Follow-Up Studies, HIV Infections blood, HIV Infections complications, Hemoglobins analysis, Humans, Male, Middle Aged, Pacific Islands epidemiology, Risk Factors, South America epidemiology, Young Adult, Anemia etiology, Anti-HIV Agents adverse effects, HIV Infections drug therapy
- Abstract
Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration., Methods: Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region., Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine., Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.
- Published
- 2012
- Full Text
- View/download PDF
28. Cancer in HIV-infected persons from the Caribbean, Central and South America.
- Author
-
Fink VI, Shepherd BE, Cesar C, Krolewiecki A, Wehbe F, Cortés CP, Crabtree-Ramírez B, Padgett D, Shafaee M, Schechter M, Gotuzzo E, Bacon M, McGowan C, Cahn P, and Masys D
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, Caribbean Region epidemiology, Central America epidemiology, Cohort Studies, Female, HIV Infections complications, HIV Infections diagnosis, HIV Infections drug therapy, Hodgkin Disease complications, Hodgkin Disease diagnosis, Hodgkin Disease epidemiology, Humans, Incidence, Lymphoma, AIDS-Related complications, Lymphoma, AIDS-Related diagnosis, Male, Middle Aged, Neoplasms classification, Sarcoma, Kaposi complications, Sarcoma, Kaposi diagnosis, South America epidemiology, HIV Infections epidemiology, Lymphoma, AIDS-Related epidemiology, Neoplasms complications, Neoplasms epidemiology, Sarcoma, Kaposi epidemiology
- Abstract
Background: HIV-infected individuals have heightened cancer risk. With the advent of highly active antiretroviral therapy (HAART), the frequency of some AIDS-defining cancers (ADC) has decreased although certain non-AIDS-defining cancers (NADC) are becoming more frequent. Cancers among HIV-infected individuals in Latin American and the Caribbean have not yet been carefully studied., Methods: Cancer cases among the Caribbean, Central and South American network for HIV Research (CCASAnet) cohort were identified reviewing clinical records and pre-existing databases., Results: There were 406 cancers reported: 331 ADC (224 Kaposi sarcomas and 98 non Hodgkin lymphomas). Most frequent NADC (n = 75) were Hodgkin lymphoma and skin cancers. Seventy-three percent of NADC and 45% of ADC were diagnosed >1 year after HIV diagnosis. Fifty-six percent of ADC occurred before HAART start. Median time from HAART start until cancer diagnosis was 2.5 years for NADC and 0.5 years for ADC (P = <0.001). Within 3372 HAART starters, 158 were diagnosed with 165 cancers (82.4% ADC); 85 cases were previous to or concomitant with HAART initiation. Incidence of cancer after HAART initiation in 8080 person-years of follow-up was 7.2 per 1000 person-years (95% confidence interval = 5.5 to 9.3) for ADC and 2.7 (95% confidence interval = 1.8 to 4.1) for NADC; incidence was higher in the first 2 months, particularly for ADC (47.6). A pre-HAART ADC was a predictor of mortality after adjusting for age, sex, and CD4 at HAART initiation., Conclusions: ADC were the most frequent cancers in this region and were often diagnosed close to HIV diagnosis and HAART start. Incidence of cancer was highest around HAART initiation.
- Published
- 2011
- Full Text
- View/download PDF
29. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters.
- Author
-
Crabtree-Ramírez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortés C, Padgett D, Koenig S, Gotuzzo E, Cahn P, McGowan C, Masys D, and Sierra-Madero J
- Subjects
- Adult, Caribbean Region epidemiology, Cross-Sectional Studies, Female, Humans, Latin America epidemiology, Male, Multivariate Analysis, Risk Factors, Time Factors, Antiretroviral Therapy, Highly Active methods
- Abstract
Background: Starting HAART in a very advanced stage of disease is assumed to be the most prevalent form of initiation in HIV-infected subjects in developing countries. Data from Latin America and the Caribbean is still lacking. Our main objective was to determine the frequency, risk factors and trends in time for being late HAART initiator (LHI) in this region., Methodology: Cross-sectional analysis from 9817 HIV-infected treatment-naïve patients initiating HAART at 6 sites (Argentina, Chile, Haiti, Honduras, Peru and Mexico) from October 1999 to July 2010. LHI had CD4(+) count ≤200 cells/mm(3) prior to HAART. Late testers (LT) were those LHI who initiated HAART within 6 months of HIV diagnosis. Late presenters (LP) initiated after 6 months of diagnosis. Prevalence, risk factors and trends over time were analyzed., Principal Findings: Among subjects starting HAART (n = 9817) who had baseline CD4(+) available (n = 8515), 76% were LHI: Argentina (56%[95%CI:52-59]), Chile (80%[95%CI:77-82]), Haiti (76%[95%CI:74-77]), Honduras (91%[95%CI:87-94]), Mexico (79%[95%CI:75-83]), Peru (86%[95%CI:84-88]). The proportion of LHI statistically changed over time (except in Honduras) (p≤0.02; Honduras p = 0.7), with a tendency towards lower rates in recent years. Males had increased risk of LHI in Chile, Haiti, Peru, and in the combined site analyses (CSA). Older patients were more likely LHI in Argentina and Peru (OR 1.21 per +10-year of age, 95%CI:1.02-1.45; OR 1.20, 95%CI:1.02-1.43; respectively), but not in CSA (OR 1.07, 95%CI:0.94-1.21). Higher education was associated with decreased risk for LHI in Chile (OR 0.92 per +1-year of education, 95%CI:0.87-0.98) (similar trends in Mexico, Peru, and CSA). LHI with date of HIV-diagnosis available, 55% were LT and 45% LP., Conclusion: LHI was highly prevalent in CCASAnet sites, mostly due to LT; the main risk factors associated were being male and older age. Earlier HIV-diagnosis and earlier treatment initiation are needed to maximize benefits from HAART in the region.
- Published
- 2011
- Full Text
- View/download PDF
30. [Serum markers of hepatitis B among hospital personnel before vaccination].
- Author
-
Wehbe F, Berthier C, Yvart J, Attali P, Buffet C, and Champsaur H
- Subjects
- Adult, Female, Hepatitis B Antibodies analysis, Hepatitis B Surface Antigens analysis, Humans, Male, Middle Aged, Hepatitis B immunology, Personnel, Hospital, Vaccination
- Published
- 1985
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.